Study of Some SNPs for PIK3CA Gene in Laryngeal Cancer Cells line (HEP-2)
الباحثون LUBNA SAMI ALI، NISREEN J. MOHAMMED, RANA A. GHALEB3,SHAIMAA A. AL-OUBAIDY
المجلةInternational Journal of Pharmaceutical Research
مختصر البحثMutations of the phosphatidyl-inositol 3-kinase (PI3k) Pathway in the head and neck squamous cell carcinoma ( HNSCC) may accelerate the malignant cells formation which is already genetically aberrant, resulting in further genomic aberrations in known cancer genes. The PI3KCA gene, which codes the catalytic subunit p110α, is one of the important mutated oncogenes found in human cancers and considered as a tool for diagnostic and therapeutic targets. The results of the sequence of PCR products of amplified gene PI3KCA in the hep2 cell line include three detected SNPs and were found to be previously known as rs138281424, rs1057519925, and rs751920344 for the detected G535A, G703A, and T606C, respectively. PIK3CA was a serious potential target for pathway-specific, kinase-inhibitor-based therapies in laryngeal cancer.
Cytotoxic Effect of Pioglitazone in Colorectal Cancer Cell Line SW480
الباحثونLubna Sami ALI ، Ali M. JANABI
المجلةLatin American Journal of Pharmacy
مختصر البحثColorectal cancer has several etiologies. It ranks third in terms of cancer frequency and is the
second leading cause of cancer-related deaths globally. Drug repurposing involves identifying new therapeutic
applications for medicines that are already available. pioglitazone is a thiazolidinedione medication that aids
in regulating elevated blood glucose levels by enhancing the body’s sensitivity to insulin. We tested the pioglitazone effect on colon cancer cell line by measuring caspase-3, CDH1, STAT3 gene expression, and COX2
protein level. This study used pioglitazone at various concentrations on SW480 cells. Cell proliferation was
measured using MTT. The study also examined the effect of pioglitazone on caspase-3, CDH1, and STAT3
gene expression using quantitative real-time polymerase chain reaction. The Elisa technique measured cox2
protein. Cell proliferation tests showed the dose-dependent anticancer effects of pioglitazone. Pioglitazone
upregulates caspase-3 and CDH1 gene expression with downregulation of STAT3 and decreases COX2 protein
levels. Pioglitazone might be a promising option for studying colon cancer and developing anti-cancer medications. This medication has the potential to treat cancer because of its anti-inflammatory, antiproliferative,
and antimetastatic characteristics.